Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.
Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, Alserawan L, Navarro S, Albiol N, Lozano M, Charry P, Magnano L, Rivero A, Correa JG, Mozas P, Cortés-Bullich A, Jiménez-Vicente C, Giné E, Montoro-Lorite M, Ramos C, Ayora P, Calderón H, Sánchez-Castañón M, Benítez-Ribas D, Mata-Molanes JJ, Rojas K, Setoaín X, Rodríguez S, Murias A, Alcubilla P, Varea S, Olesti E, Bachiller M, Calvo-Orteu M, Sans-Pola C, Sáez-Peñataro J, de Larrea CF, López-Guillermo A, González-Navarro EA, Juan M, Delgado J.
Martínez-Cibrián N, et al. Among authors: correa jg.
Hemasphere. 2025 Sep 11;9(9):e70166. doi: 10.1002/hem3.70166. eCollection 2025 Sep.
Hemasphere. 2025.
PMID: 40951523
Free PMC article.